Biomind Labs Inc.
BMND
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 765.05% | -13.78% | -12.98% | 4.24% | 46.33% |
| Depreciation & Amortization | -100.00% | -- | -- | 0.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 484.64% | -4.29% | -14.75% | 4.07% | 2.16% |
| Operating Income | -484.64% | 4.29% | 14.75% | -4.07% | -2.16% |
| Income Before Tax | -427.51% | -197.97% | 45.07% | 64.12% | 163.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -427.51% | -197.97% | 45.07% | 64.12% | 163.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -427.51% | -197.97% | 45.07% | 64.12% | 163.32% |
| EBIT | -484.64% | 4.29% | 14.75% | -4.07% | -2.16% |
| EBITDA | -498.59% | 1.81% | 12.98% | -4.24% | -1.65% |
| EPS Basic | -431.82% | -160.00% | 46.43% | 64.00% | 161.11% |
| Normalized Basic EPS | -421.43% | -166.67% | 50.00% | 31.25% | 160.87% |
| EPS Diluted | -431.82% | -160.00% | 46.43% | 64.00% | 161.11% |
| Normalized Diluted EPS | -421.43% | -166.67% | 50.00% | 31.25% | 160.87% |
| Average Basic Shares Outstanding | 0.00% | 4.16% | 3.76% | 3.76% | 3.76% |
| Average Diluted Shares Outstanding | 0.00% | 4.16% | 3.76% | 3.76% | 3.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |